Drugs & Therapy Perspectives

, Volume 34, Issue 7, pp 317–321 | Cite as

Manage cutaneous adverse effects associated with tumour necrosis factor inhibitors with topical corticosteroids and oral antibiotics

  • Adis Medical WritersEmail author
Drug Reactions and Interactions


Cutaneous adverse effects (CAEs), such as eczema, psoriasis, and skin infections, are common in patients receiving tumour necrosis factor inhibitors (TNFIs; e.g. adalimumab, etanercept and infliximab). Once a CAE is diagnosed, patients should receive appropriate dermatological care, as this may avoid cessation of TNFI therapy. Topical corticosteroids are the mainstay of therapy for numerous skin lesions, while oral antibiotics are effective in the treatment of superinfections.



The preparation of this review was not supported by any external funding.

Compliance with ethical standards

Conflict of interest

The article was adapted from the American Journal of Clinical Dermatology, 2017;18(6):771–87 by employees of Adis/Springer, who are responsible for the article content and declare no conflicts of interest.


  1. 1.
    Fidder HH, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study. Gut. 2009;58(4):501–8.CrossRefGoogle Scholar
  2. 2.
    Cleynen I, Van Moerkercke W, Billiet T, et al. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease. Ann Intern Med. 2016;164(1):10–22.CrossRefGoogle Scholar
  3. 3.
    Segaert S, Hermans C. Clinical signs, pathophysiology and management of cutaneous side effects of anti-tumor necrosis factor agents. Am J Clin Dermatol. 2017;18(6):771–87.CrossRefGoogle Scholar
  4. 4.
    Mälkönen T, Wikström A, Heiskanen K, et al. Skin reactions during anti-TNFα therapy for pediatric inflammatory bowel disease: a 2-year prospective study. Inflamm Bowel Dis. 2014;20(8):1309–15.CrossRefGoogle Scholar
  5. 5.
    Hernández MV, Sanmartí R, Cañete JD, et al. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases. Arthritis Care Res. 2013;65(12):2024–31.CrossRefGoogle Scholar
  6. 6.
    Fréling E, Baumann C, Cuny JF, et al. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol. 2015;110(8):1186–96.CrossRefGoogle Scholar
  7. 7.
    Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-c-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63(4):567–77.CrossRefGoogle Scholar
  8. 8.
    Hellström AE, Färkkilä M, Kolho KL. Infliximab-induced skin manifestations in patients with inflammatory bowel disease. Scand J Gastroenterol. 2016;51(5):563–71.CrossRefGoogle Scholar
  9. 9.
    Guerra I, Pérez-Jeldres T, Iborra M, et al. Incidence, clinical characteristics, and management of psoriasis induced by anti-TNF therapy in patients with inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis. 2016;22(4):894–901.CrossRefGoogle Scholar
  10. 10.
    Pugliese D, Guidi L, Ferraro PM, et al. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther. 2015;42(7):880–8.CrossRefGoogle Scholar
  11. 11.
    Afzali A, Wheat CL, Hu JK, et al. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis. 2014;8(6):480–8.CrossRefGoogle Scholar
  12. 12.
    George LA, Gadani A, Cross RK, et al. Psoriasiform skin lesions are caused by anti-TNF agents used for the treatment of inflammatory bowel disease. Dig Dis Sci. 2015;60(11):3424–30.CrossRefGoogle Scholar
  13. 13.
    Protic M, Schoepfer A, Yawalkar N, et al. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels. Scand J Gastroenterol. 2016;51(12):1482–8.CrossRefGoogle Scholar
  14. 14.
    Flendrie M, Vissers WH, Creemers MC, et al. Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7(3):R666–76.CrossRefGoogle Scholar
  15. 15.
    Lee HH, Song IH, Friedrich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-α antagonists. Br J Dermatol. 2007;156(3):486–91.CrossRefGoogle Scholar
  16. 16.
    Huang VWM, Dhami N, Fedorak D, et al. A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels. Can J Gastroenterol. 2015;29(1):35–40.Google Scholar
  17. 17.
    Darrigade AS, Milpied B, Truchetet ME, et al. Pattern and severity of psoriasiform eruptions in patients with inflammatory bowel diseases, arthritis or skin inflammatory disorders treated with TNF-alpha inhibitors. Acta Derm Venereol. 2017;97(6):731–4.CrossRefGoogle Scholar
  18. 18.
    Harrison MJ, Dixon WG, Watson KD, et al. British Society for Rheumatology Biologics Register Control Centre Consortium. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68(2):209–15.CrossRefGoogle Scholar
  19. 19.
    Esmailzadeh A, Yousefi P, Farhi D, et al. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. Dermatology. 2009;219(3):263–7.CrossRefGoogle Scholar
  20. 20.
    McKenna MR, Stobaugh DJ, Deepak P. Melanoma and nonmelanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointestin Liver Dis. 2014;23(3):267–71.PubMedPubMedCentralGoogle Scholar
  21. 21.
    van Lümig PP, Menting SP, van den Reek JM, et al. An increased risk of non-melanoma skin cancer during TNF-inhibitor treatment in psoriasis patients compared to rheumatoid arthritis patients probably relates to disease-related factors. J Eur Acad Dermatol Venereol. 2015;29(4):752–60.CrossRefGoogle Scholar
  22. 22.
    Fulchiero GJ Jr, Salvaggio H, Drabick JJ, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. J Am Acad Dermatol. 2007;56(5 Suppl):S65–7.CrossRefGoogle Scholar
  23. 23.
    Tauber M, Beneton N, Reygagne P, et al. Alopecia areata developing during ustekinumab therapy: report of two cases. Eur J Dermatol. 2013;23(6):912–3.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Guttman-Yassky E, Ungar B, Noda S, et al. Extensive alopecia areata is reversed by IL-12/IL-23p40 cytokine antagonism. J Allergy Clin Immunol. 2016;137(1):301–4.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations